Translating a deep
expertise in growth
factor biology
Read more
Pipeline of growth
factor modulating
therapies
Read more
Building a company
focused on treating
fibrosis
Read more

Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas

News & Events
PR

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

December 14th, 2023
Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung- restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

PR

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

November 29th, 2023
Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer. As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).

PR

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

October 11th 2023
Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

“WE ARE DETERMINED TO IMPROVE THE LIVES OF PATIENTS WITH FIBROTIC DISEASES. WE ARE BUILDING A LEADING COMPANY THAT COMBINES TRANSFORMATIVE SCIENCE WITH THE COMMITMENT AND PASSION OF OUR EXPERIENCED TEAM, PARTNERS, AND INVESTORS.”

-

Tim Knotnerus, Chief Executive Officer